Melatonin

Generic Name: Melatonin

Brand Names: Circadin, Slenyto, Melatonin Neurim

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₂O_₂

CAS Number: 73-31-4

Unique Ingredient Identifier: JL5DK93RCL

Background: Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence ...

Indication: Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for ...

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Matched Placebo
Drug: Melatonin

First Posted Date: 2015-04-30

Last Posted Date: 2016-02-24

Lead Sponsor: Khon Kaen University

Target Recruit Count: 39

Registration Number: NCT02430298

Locations: 🇹🇭
Ubon Ratchathani Cancer Hospital, Ubon Ratchathani, Thailand

The Effect of Premedication With Melatonin on Postoperative Recovery From Bariatric Surgery

Phase 4

Completed

Conditions: Recovery From Bariatric Surgery

Interventions: Drug: placebo
Drug: Melatonin

First Posted Date: 2015-04-22

Last Posted Date: 2017-04-27

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 60

Registration Number: NCT02424071

Locations: 🇮🇱
Sheba Medical Center, Ramat Gan, Israel

Anxiolytic and Analgesic Effects of Melatonin

Phase 3

Completed

Conditions: Anxiety

Interventions: Drug: Melatonin
Drug: Placebo

First Posted Date: 2015-03-11

Last Posted Date: 2021-09-02

Lead Sponsor: Herlev Hospital

Target Recruit Count: 36

Registration Number: NCT02386319

Locations: 🇩🇰
Herlev Hospital, Herlev, Denmark

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3

Terminated

Conditions: Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders

Interventions: Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium

First Posted Date: 2015-03-02

Last Posted Date: 2018-02-28

Lead Sponsor: Hannover Medical School

Target Recruit Count: 407

Registration Number: NCT02374567

Locations: 🇩🇪
Bezirkskrankenhaus Augsburg, Augsburg, Germany
🇩🇪
Krankenhaus Hedwigshöhe, Berlin, Germany
🇩🇪
Hannover Medical School, Hannover, Germany

and more 2 locations

Melatonin for Nocturia in Parkinson's Disease

Phase 2

Conditions: Nocturia
Parkinson's Disease

Interventions: Drug: Melatonin

First Posted Date: 2015-02-10

Last Posted Date: 2015-02-10

Lead Sponsor: University College, London

Target Recruit Count: 20

Registration Number: NCT02359448

Locations: 🇬🇧
National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, London, United Kingdom

Bringing Relief to Adolescents Naturally Using Melatonin for Migraine

Phase 2

Completed

Conditions: Migraine in Adolescents

Interventions: Other: Placebo
Drug: Melatonin

First Posted Date: 2015-01-22

Last Posted Date: 2021-09-09

Lead Sponsor: Amy Gelfand

Target Recruit Count: 31

Registration Number: NCT02344316

Locations: 🇺🇸
UCLA Headache Research and Treatment Program, Los Angeles, California, United States
🇺🇸
UCSF Pediatric Brain Center, San Francisco, California, United States

Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

Phase 3

Terminated

Conditions: Breast Cancer - Female

Interventions: Drug: Placebo
Drug: Melatonin

First Posted Date: 2015-01-07

Last Posted Date: 2023-03-30

Lead Sponsor: Virginia Commonwealth University

Target Recruit Count: 80

Registration Number: NCT02332928

Locations: 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

Dose Assessment of Melatonin in Sepsis Trial

Phase 1

Withdrawn

Conditions: Sepsis

Interventions: Drug: Melatonin

First Posted Date: 2014-12-18

Last Posted Date: 2017-04-21

Lead Sponsor: University of Aberdeen

Registration Number: NCT02319265

Locations: 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom

Melatonin for Delirium Prophylaxis

Phase 4

Withdrawn

Conditions: Delirium

Interventions: Other: Placebo
Drug: Melatonin

First Posted Date: 2014-11-04

Last Posted Date: 2021-10-07

Lead Sponsor: University of British Columbia

Registration Number: NCT02282241

Locations: 🇨🇦
Vancouver Coastal Health, Vancouver, British Columbia, Canada

Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)

Phase 2

Completed

Conditions: Reperfusion Injury

Interventions: Drug: Sodium chloride solution
Drug: Antithrombin-III
Drug: Infliximab
Drug: Apotransferrin
Drug: Human recombinant erythropoietin
Drug: C1-Inhibitor
Drug: Glutathione
Drug: Alfa-tocopherol
Drug: Melatonin
Drug: Epoprostenol

First Posted Date: 2014-09-26

Last Posted Date: 2024-08-23

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 143

Registration Number: NCT02251041

Locations: 🇧🇪
University Hospitals Leuven, Leuven, Belgium

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy